The quantitative evaluation of Artificial Intelligence (AI) systems in a clinical context is a challenging endeavor, where the development and implementation of meaningful performance metrics is still in its infancy. Here, we propose a scientific concept, Artificial Intelligence Prospective Randomized Observer Blinding Evaluation (AI-PROBE) for quantitative clinical performance evaluation of radiology AI systems within prospective randomized clinical trials. Our evaluation workflow encompasses a study design and a corresponding radiology Information Technology (IT) infrastructure that randomly blinds radiologists with regards to the presence of positive reads as provided by AI-based image analysis systems. To demonstrate the applicability of our AI-evaluation framework, we present a first prospective randomized clinical trial on investigating the effect of automatic identification of Intra-Cranial Hemorrhage (ICH) in emergent care head CT scans on radiology study Turn-Around Time (TAT) in a clinical environment. Here, we acquired 620 consecutive non-contrast head CT scans from CT scanners used for inpatient and emergency room patients at a large academic hospital over a time period of 14 consecutive days. Immediately following image acquisition, scans were automatically analyzed for the presence of ICH using commercially available software (Aidoc, Tel Aviv, Israel). Cases identified as positive for ICH by AI (ICH-AI+) were automatically flagged in the radiologists' reading worklists, where flagging was randomly switched off with a probability of 50%. Study TAT was measured automatically as the time difference between study completion and first clinically communicated study reporting, with time stamps for these events automatically retrieved from various radiology IT systems. TATs for flagged cases (73 ± 143 min) were significantly lower than TATs for non-flagged (132 ± 193 min) cases (p<0.05, one-sided t-test), where 105 of the 122 ICH-AI+ cases were true positive reads. Total sensitivity, specificity, and accuracy over all analyzed cases were 95.0%, 96.7%, and 96.4%, respectively. We conclude that automatic identification of ICH reduces study TAT for ICH in emergent care head CT settings, which carries the potential for improving clinical management of ICH by accelerating clinically indicated therapeutic interventions. In a broader context, our results suggest that our AI-PROBE framework can contribute to a systematic quantitative evaluation of AI systems in a clinical workflow environment with regards to clinically meaningful performance measures, such as TAT or diagnostic accuracy metrics.
INTRODUCTION
A key challenge for the adoption of Artificial Intelligence (AI) systems in a clinical context is the generic lack of standards for objectively evaluating such systems with regards to clinically meaningful performance metrics. Solely relying on classical performance metrics from machine learning or signal processing, such as Receiver Operating Characteristic (ROC) analysis of diagnostic accuracy or computation times, may be helpful for initially evaluating and comparing AI systems on benchmark data in isolation from their actual clinical application context, but they fall short at evaluating the clinical usefulness of AI systems in real-world settings.
A fully automated diagnosis by AI systems without human intervention would potentially require a 'strong' artificial intelligence to be socially acceptable. As artificial intelligence, despite its 70-year history, is still in its infancy, the deployment and operation of AI systems in medicine will continue to require human control and supervision in the foreseeable future. Hence, an objective evaluation of contemporary AI systems can only be based on the interplay of This is a pre-print version of a publication that was presented at the SPIE Medical Imaging 2020 Conference, Houston, TX, February 15-20, 2020. such systems with human experts using them in a real-world context, such as radiologists in a clinical reading workflow environment. Here, it is important to understand that not only the performance of the 'inference machine' in AI systems, such as their classification or regression quality, determines their real-world usefulness, but that other factors, such as user interface, ease of access, user motivation, etc., may play a critical role as well.
Although most of the academic literature on AI in medical imaging focuses on comparing the performance of different AI systems on given data, such as in various 'competitions' on publicly available benchmark data, see e.g. [1] , [2] , [3] , it is often more important to investigate the effects of deployment of a single AI system based on quantitative measurable clinical parameters. The reason for this is that AI systems, such as other capital investments in the healthcare enterprise, are usually not introduced in a clinical workflow environment for the sake of comparing them to each other. Rather a decision is made for deploying a single system in a given environment, based on administrative, financial or business development considerations. In radiology, for example, the challenge of evaluating the clinical usefulness of an AI system would be to compare the radiologists' performance with and without using the system, where clinically meaningful performance measures are determined, such as diagnostic accuracy or study turnaround time, resulting from human-machine inter-operability.
To address this challenge, we propose a scientific framework, Artificial Intelligence Prospective Randomized Observer Blinding Evaluation (AI-PROBE) for quantitative clinical performance evaluation of radiology AI systems within prospective randomized clinical trials. Our evaluation workflow encompasses a study design and a corresponding radiology Information Technology (IT) infrastructure that randomly blinds radiologists with regards to the presence of positive reads as provided by AI-based image analysis systems.
In the following, we will explain the basic idea of AI-PROBE, describe its clinical application within a prospective randomized clinical trial for AI-based detection of ICH in emergent care head CT scans, and will report study results on radiology turnaround times for this clinical application. This work is embedded in our group's endeavor to expedite artificial intelligence in biomedical imaging by means of advanced pattern recognition and machine learning methods for computational radiology and radiomics, e.g. .
SCIENTIFIC CONCEPT

Shortcomings of Retrospective AI evaluation
The potential of retrospective performance analysis of radiology AI systems is limited and subject to manifold systematic errors. A typical scenario for retrospective analysis would be to compare certain clinical outcome measures before and after deployment of an AI system into a radiology workflow. Such systematic errors include temporal changes before and after AI deployment, such as changing radiology staffing, work organization patterns, or temporal shifts of case distributions, to name a few. In order to avoid such systematic errors, it follows that retrospective AI evaluation approaches, although widely used, should be replaced by prospective evaluation methods. However, introducing prospective radiology AI evaluation is challenging, because (i) there is limited experience and literature on prospective approaches to radiology AI system evaluation, (ii) such approaches imply significant both organizational and technical efforts.
Artificial Intelligence Prospective Randomized Observer Blinding Evaluation (AI-PROBE)
To address this challenge, we propose a scientific concept, Artificial Intelligence Prospective Randomized Observer Blinding Evaluation (AI-PROBE), for quantitative clinical performance evaluation of radiology AI systems within prospective randomized clinical trials. Our evaluation workflow encompasses a study design that randomly blinds radiologists with regards to the presence of reading results provided by AI-based image analysis systems. There are various options within this concept, which can be chosen according to the clinical needs of a specific evaluation situation.
(i) The first option, AI-PROBE-1, is specifically suited for radiology worklist prioritization, where radiologists may only be interested to be informed about positive reads, for example, flagging of cases, in which an AI system has identified an emergent finding, such as an intracranial hemorrhage on a head CT scan. In this scenario, having no flag associated with a radiology study does not provide any information to the observer, as to whether she was blinded about the AI reading results based on the AI-PROBE clinical trial design, whether the study was analyzed at all, or whether it was analyzed, but has been rated by the AI system as a negative read for the examined condition. This is a pre-print version of a publication that was presented at the SPIE Medical Imaging 2020 Conference, Houston, TX, February 15-20, 2020. (ii) The second option, AI-PROBE-2, randomly blinds the observer about the results of AI system reads, but flags all cases that have been analyzed by the AI system. In this scenario, different types of flags need to be utilized. In the simplest case, the user would have to be informed, whether a case was read as positive or negative by the AI system for an examined condition, such as for the presence or absence of an intracranial hemorrhage. Having no flag associated with a given radiology study informs the user that there are no AI reading results available for this case for any reason, be it that the user was blinded for the given case according to the AI-PROBE clinical trial design, or that there are no AI reading results available for any technical reasons. Such technical reasons can be manifold, including (i) that a given scanner or imaging archive was not connected to the AI system, (ii) the case was not sent for analysis, (iii) the case was sent, but not analyzed, (iv) the case was analyzed, but no results are available, such as induced by network communication or inference machine processing delays. Note that this list of reasons is not exhaustive, and that an arbitrary number of additional flags may be introduced to inform the user about such reasons.
A free parameter that needs to be considered is the probability P for selecting cases, for which radiologists will be blinded with regards to AI reading results. For simplicity, in the trial on intracranial hemorrhage reported below, we chose an AI-PROBE-1 study design with P=50%.
We emphasize that multiple organizational and technical challenges have to be met simultaneously for implementing an AI-PROBE study design. These challenges include, but are not limited to, (i) acquiring Institutional Review Board approval for radiologists' participation in such prospective trials, (ii) aligning the interests of diverse stakeholders, including radiologists, hospital administrators, and AI solution vendors, and (iii) significant interface programming efforts for automatically retrieving heterogeneous information from multiple radiology and hospital IT systems, such as various time stamps for events related to technical processing or human intervention.
CLINICAL APPLICATION: INTRACRANIAL HEMORRHAGE DETECTION TRIAL
Clinical Relevance: To demonstrate the applicability of our AI-evaluation framework, we present a first prospective randomized trial on investigating the effect of automatic identification of Intra-Cranial Hemorrhage (ICH) in emergent care head CT scans on radiology study Turn-Around Time (TAT) in a clinical environment. Timely detection of ICH on medical imaging studies is critical, because delayed therapeutic interventions in emergency settings may be detrimental for patient outcome. For example, in hemorrhagic stroke, the American Heart Association (AHA)/American Stroke Association (ASA) 2018 guidelines for early management emphasize the time-dependent benefit of tissue plasminogen activator (tPA) therapy [55] . Patients with ischemic stroke must be identified as soon as possible so that tPA can be administered within 3-4.5 hours of symptom onset [55] . A non-contrast head CT scan, which must be negative for hemorrhage, is a required diagnostic test before tPA can be administered in a timely manner [56, 57, 58] . The clinical outcomes of patients receiving tPA within a designated time limit are closely linked to time of treatment [58, 59] . Besides hemorrhagic stroke, there are numerous other clinical conditions, in which ICH will lead to rapid increase of intracranial pressure, where early detection and treatment of ICH can significantly reduce patient morbidity and mortality.
Data and Methods:
A total of 620 consecutive non-contrast head CT scans from two CT scanners used for inpatient and This is a pre-print version of a publication that was presented at the SPIE Medical Imaging 2020 Conference, Houston, TX, February 15-20, 2020. emergency room patients at a large academic hospital (Strong Memorial Hospital, University of Rochester Medical Center) were prospectively acquired over a time period of 14 consecutive days. Immediately following image acquisition, scans were automatically analyzed for the presence of intracranial hemorrhage (ICH) using commercially available software (Aidoc, Tel Aviv, Israel). Cases identified as positive for ICH by AI (ICH-AI+) were automatically flagged in the radiologists' reading worklists, where flagging was randomly switched off with a probability P=50%. Study turnaround time (TAT) was measured automatically as the time difference between study completion time (=study accessible to radiologists for reporting) to study reporting time (=first report visible to clinicians, regardless whether preliminary or final). Time stamps for calculating TAT were automatically retrieved from various radiology IT systems. The hypothesis that TATs for non-flagged ICH-AI+ cases were higher than for flagged ICH-AI+ cases was tested using a one-sided heteroscedastic t-test. Total sensitivity, specificity, and accuracy for ICH detection were calculated for all analyzed 620 cases, where final radiology reports served as ground truth.
RESULTS
A total of 122 ICH-AI+ cases were found among the total number of analyzed 620 non-contrast head CT cases, of which 66 cases were flagged. Study TAT was measured automatically as the time difference between study completion time, i.e., when the study became accessible to radiologists for reporting, and the study reporting time, i.e., when the first report was completed that was visible to clinicians, regardless whether this report legally qualified as a preliminary or as a final report. Figure 1 summarizes our results on the distributions of radiology study turnaround times (TAT), comparing flagged and non-flagged ICH-AI+ cases. It can be seen that the TAT distributions for flagged and nonflagged cases are different, with higher TATs observed for non-flagged ICH-AI+ cases. This is confirmed by statistical analysis: TATs for flagged cases (73 ± 143 min) were significantly lower than TATs for non-flagged (132 ± 193 min) cases (p<0.05, one-sided t-test). A total of 105 of the 122 ICH-AI+ cases were true positive reads, as verified by human review of final radiology reports. Total sensitivity, specificity, and accuracy over all analyzed 620 cases were 95.0%, 96.7%, and 96.4%, respectively.
NEW AND BREAKTHROUGH WORK
We introduce a scientific framework, Artificial Intelligence Prospective Randomized Observer Blinding Evaluation (AI-PROBE) for quantitative clinical performance evaluation of radiology AI systems within prospective randomized clinical trials. Our evaluation workflow encompasses a study design and a corresponding radiology information technology infrastructure that randomly blinds radiologists with regards to the presence of positive reads as provided by AI-based image analysis systems. To demonstrate the applicability of our AI-evaluation framework, we present a first prospective randomized clinical trial on investigating the effect of automatic identification of Intra-Cranial Hemorrhage (ICH) in 620 emergent care head CT scans on radiology study Turn-Around Time (TAT) in a clinical environment. Our results suggest that notifying radiologists on automatically detected ICH reduces TAT for reporting ICH to clinicians in emergency setting head CT scans, as shown by our prospective, randomized clinical study. Such reduced TAT may expedite clinically indicated therapeutic interventions.
CONCLUSION
We conclude from our prospective randomized clinical trial that automatic identification of Intra-Cranial Hemorrhage (ICH) reduces radiology study turnaround times for ICH in emergent care head CT settings, which carries the potential for improving clinical management of ICH by accelerating clinically indicated therapeutic interventions. In a broader scientific context, our results suggest that the proposed AI-PROBE framework can contribute to a systematic quantitative evaluation of AI systems in a real-world workflow environment with regards to clinically meaningful performance metrics, such as radiology study turnaround times or diagnostic accuracy measures.
